05 Jun ASCO24: Early Breast Cancer: Impact of race/ethnicity on the MammaPrint genomic assay risk and prognosis
MedicalResearch.com Interview with:
Dr. Patel
Rima Patel, MD
Assistant Professor, Division of Hematology/Oncology
The Tisch Cancer Institute
Icahn School of Medicine at Mount Sinai
MedicalResearch.com: What is the background for this study?
Response: The 21-gene Oncotype DX Recurrence Score (RS) and 70-gene MammaPrint (MP) assays provide prognostic information for distant recurrence and are used to guide chemotherapy use in hormone receptor (HR)-positive, HER2-negative early breast cancer (EBC). Previous reports have demonstrated racial differences in the prognostic accuracy of the RS. In both the TAILORx and RxPONDER trials, Black women with low genomic risk (RS 0-25) had a higher recurrence risk than White women. In another study using the NCDB database, Black race was associated with worse overall survival in multivariate models including RS. The impacts of race/ethnicity on the MammaPrint assay are unknown.
MedicalResearch.com: What are the main findings? Do the findings vary with the assay used?
Response: We found that in an NCDB cohort of 6096 women with ER+, HER2-negative breast cancer and 0-3 positive axillary nodes who had the 70-gene MammaPrint assay performed, Non-Hispanic Black women (8.7% of overall population) were significantly younger compared with other racial/ethnic groups, and were more likely to have larger tumors, higher grade tumors, positive axillary LNs, and a high-risk MammaPrint.
Overall survival (OS) was not significantly different for non-Hispanic Black women compared with other racial/ethnic groups when evaluated in multivariate models adjusted for prognostic covariates, although non-Hispanic Black women had the worst OS when not adjusted for other covariates.
Although OS was not significantly different for non-Hispanic Black compared with other racial/ethnic groups in either the low-risk or high-risk MammaPrint groups, this evaluation was limited by the lack of a significant OS difference by race/ethnicity in the overall population when adjusted for other covariates.
MedicalResearch.com: What should readers take away from your report?
Response: Non-Hispanic Black women were more likely to have larger tumors, higher grade tumors, lymph node involvement and a high-risk MammaPrint. While we did not find a difference in overall survival by race/ethnicity in the MammaPrint high-risk or low-risk group, these findings may be limited by the lower proportion of non-Hispanic Black and Hispanic women in the overall population and lack of overall survival difference by race/ethnicity in the overall population. Hence, the impact of race/ethnicity on the MammaPrint assay is still unclear.
MedicalResearch.com: What recommendations do you have for future research as a results of this study?
Response: Future research should evaluate the impact of race/ethnicity on the MammaPrint assay in other cohorts with a greater proportion of racial/ethnic minorities, including Non-Hispanic Black and Hispanic women.
No disclosures.
Citation: ASCO 2024 poster:
Rima Patel, MD (presenter); Amy Tiersten, MD; Joseph Sparano, MD
Abstract Number: 564
Abstract Title: Impact of race/ethnicity on the MammaPrint genomic assay risk and prognosis in early breast cancer (EBC): A National Cancer Database (NCDB) analysis
Session Type: PosterSession Title: Breast Cancer—Local/Regional/Adjuvant June 2 2024
The information on MedicalResearch.com is provided for educational purposes only, and is in no way intended to diagnose, cure, or treat any medical or other condition.
Some links may be sponsored. Products are not endorsed.
Always seek the advice of your physician or other qualified health and ask your doctor any questions you may have regarding a medical condition. In addition to all other limitations and disclaimers in this agreement, service provider and its third party providers disclaim any liability or loss in connection with the content provided on this website.
Last Updated on June 5, 2024 by Marie Benz MD FAAD